Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > NorthWest Biotherapeutics (NWBO)

DCVax-L Model Positive on Primary Endpoint.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Pyrrhonian Member Profile
Member Level 
Followed By 24
Posts 2,336
Boards Moderated 0
Alias Born 06/09/12
160x600 placeholder
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 11/26/2014 4:08:42 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/19/2014 3:26:04 PM
NW BIO ANNOUNCES FINANCINGS TOTALING $35 MILLION TO EXPAND AND ACCELERATE DCVAX®-L AND DCVAX®-DIRECT PROGRAMS "PR Newswire (US)" - 11/19/2014 3:20:00 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 11/14/2014 4:02:19 PM
Four Companies to Keep on Your Radar & Special Report on Emerging Beverage Contender by Small Cap IR "InvestorsHub NewsWire" - 11/10/2014 7:00:00 AM
NW BIO MAKING A JOINT POSTER PRESENTATION ON ITS DCVAX-DIRECT TRIAL AT THE 29TH ANNUAL SITC MEETING "PR Newswire (US)" - 11/7/2014 9:15:00 AM
Hot Stocks to Follow for Investment Opportunity & Special Profile "InvestorsHub NewsWire" - 11/6/2014 6:00:00 AM
The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securi... "PR Newswire (US)" - 10/28/2014 2:41:00 PM
DCVAX®-L HOSPITAL EXEMPTION PROGRAM NOW UNDER WAY IN GERMANY "PR Newswire (US)" - 10/14/2014 9:01:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/10/2014 4:31:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/8/2014 4:11:25 PM
NW BIO ANNOUNCES $11.5 MILLION FINANCING "PR Newswire (US)" - 10/7/2014 9:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/18/2014 9:24:39 AM
NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) "PR Newswire (US)" - 9/16/2014 8:00:00 AM
NW BIO CEO TO PRESENT AT SMi's 3rd ANNUAL CANCER VACCINES CONFERENCE IN LONDON "PR Newswire (US)" - 9/15/2014 8:00:00 AM
NW BIO TO PRESENT UPDATES AT RODMAN RENSHAW 16TH ANNUAL GLOBAL INVESTMENT CONFERENCE "PR Newswire (US)" - 9/8/2014 8:15:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/25/2014 4:26:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/19/2014 5:29:40 PM
NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING "PR Newswire (US)" - 8/19/2014 2:44:00 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/15/2014 6:02:42 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 8/14/2014 4:17:12 PM
NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES "PR Newswire (US)" - 8/14/2014 11:47:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/11/2014 5:17:29 PM
NW BIO OBTAINS APPROVALS FOR ENHANCEMENTS OF PHASE III TRIAL OF DCVAX®-L FOR GBM BRAIN CANCER "PR Newswire (US)" - 8/11/2014 8:15:00 AM
Pyrrhonian Member Level  Friday, 04/18/14 07:09:04 PM
Re: None
Post # of 25117 
DCVax-L Model Positive on Primary Endpoint.


This was from alphapuppy a bit ago:

Quote:
Discloser: I am long this stock; I have no inside information; I am a clinical researcher.

Hypothesis 1: The Control Patients in the DCVax-L GBM trial should relapse at a rate similar to what was shown in the Stupp trial. The Stupp trial is the best GBM data available and represents the standard of care for GBM patients. In order to compare the Stupp Trial to the current DCVax-L trial control patients, however, one must review the eligibility requirements for each trial. The DCVax-L Trial only allows patients to enter the trial, if “surgical resection with the intent of a gross total or near gross total resection” can be completed. The Stupp Trial contained 17% patient who just had a biopsy only and another 44% of the patients who only had a partial resection. Extent of surgical resection is a major prognostic factor for these tumors and historical reviews have shown the degree which the various surgical procedures can change survival rates. The Median progression free survival (PFS) for all patients in the Stupp trial was 6.9 months. When one applies algebra proportions to correct for the differences in prognosis between the trials in terms of surgical extent, the likely median PFS for the control patients in the DCVax-L trial should be around 9 months.

Hypothesis 2: Given that we know the current number of events in the total DCVax-L trial at this time (first interim analysis) is 67, then one can model the control arm PFS to be similar to the corrected Stupp trial results and thus obtain an estimate for the probable number of events required in the control arm of the DCVax-L trial to give a 9 month median PFS. When one does this with a Kaplan Meier plot, one obtains a result of a minimum of 30 events in the control arm with the total number of patients in the control arm of 57. Then one can deduce that the number of events in the experimental arm for the DCVax-L trial would be 67-30 or 37 events.

Hypothesis 3: Using the derived 37 events in the experimental arm, one can model the experimental arm to be similar to the Stupp trial results but, in this case only allow for just 37 events out of 114 total patients in the DCVax-L experimental arm. When one does this with a Kaplan Meier plot, the median PFS for the experimental arm returns > 17.5 month median PFS in the DCVax-L experimental arm. When one applies log-rank and Wilcoxon significance testing to the two curves one obtains a significant result of p=<.0001 and p =.00015 respectively.

My best educated guess is that the DCVax-L trial is likely going to return a positive result on the primary end point given the information that we have currently available.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist